# Safety and Efficacy of BIA 5-1058 in PAH

> **NCT06009185** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 20 (actual)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** Oral zamicastat

## Key facts

- **NCT ID:** NCT06009185
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-26
- **Primary completion:** 2022-02-17
- **Final completion:** 2022-02-17
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2023-09-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06009185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06009185, "Safety and Efficacy of BIA 5-1058 in PAH". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06009185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*